Clinical trials · New Jersey
HER2 + Breast Cancer clinical trials in New Jersey
We’re tracking 76 recruiting her2 + breast cancer studies with a site in New Jersey — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New Jersey
- NCT05827081RecruitingPhase 3
Ribociclib plus endocrine therapy for early breast cancer
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
Camden, New JerseyAges 18–100 - NCT05256745RecruitingPhase 1/Phase 2
A medicine to protect the heart during breast cancer chemotherapy
This early-phase study tests azeliragon to lower the risk of chemotherapy-related heart damage in women with early-stage breast cancer. Participants get their planned standard chemotherapy, plus the study medicine, and are monitored for safety and heart health.
Hackensack, New JerseyAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
East Brunswick, New JerseyAges 18 years+ - NCT00823654Recruiting
Blood tests during treatment to track ovarian egg supply
This study measures blood biomarkers to understand how breast cancer treatment affects a person’s future fertility (ovarian reserve). It may help patients learn more about egg supply changes after chemotherapy and hormone-related treatments.
Basking Ridge, New JerseyAges 18–44 - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Hackensack, New JerseyAges 18 years+ - NCT04852887RecruitingPhase 3
Testing shorter breast radiation after low-risk hormone breast cancer
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Pennington, New JerseyAges 50–70 - NCT05646862RecruitingPhase 3
Comparing two treatments for advanced breast cancer with a PIK3CA mutation
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
Camden, New JerseyAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Belleville, New JerseyAges 18 years+ - NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
New Brunswick, New JerseyAges 18 years+ - NCT04802759RecruitingPhase 1/Phase 2
Testing drug combinations for recurrent or advanced ER-positive breast cancer
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
Freehold, New JerseyAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Camden, New JerseyAges 18–60 - NCT07492641RecruitingPhase 3
A new drug plus letrozole for advanced HR+ breast cancer
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
East Brunswick, New JerseyAges 18 years+ - NCT07173751RecruitingPhase 3
Pumitamig for advanced triple-negative breast cancer
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
Florham Park, New JerseyAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
East Brunswick, New JerseyAges 18 years+ - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Hackensack, New JerseyAges 18 years+ - NCT06023576RecruitingPhase 2
Blood pressure control during breast cancer chemo
This study tests whether careful blood pressure management can help protect the heart during certain types of chemotherapy (anthracyclines) for breast cancer. Participants will use a smart blood pressure device and may also do an exercise test.
Basking Ridge, New JerseyAges 18 years+ - NCT06966700RecruitingPhase 3
Study of Sac-TMT in Early High-Risk Breast Cancer
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Hackensack, New JerseyAges 18 years+ - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Cherry Hill, New JerseyAges 18 years+ - NCT07060807RecruitingPhase 3
Patritumab deruxtecan for advanced breast cancer
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
Hackensack, New JerseyAges 18 years+ - NCT05559164RecruitingPhase 2
Statins to protect the heart during HER2 breast cancer treatment
This trial tests whether a cholesterol medicine (a statin) can lower the risk of heart damage in people receiving HER2-targeted breast cancer therapy. If you qualify, you may be given a statin and followed with heart tests and blood work to watch for safety and benefit.
Lakewood, New JerseyAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
East Brunswick, New JerseyAges 18–99 - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Hackensack, New JerseyAges 18 years+ - NCT06377852RecruitingPhase 3
CDK4/6 inhibitor dosing study for older adults with metastatic breast cancer
This study tests two targeted therapy drugs, palbociclib and ribociclib, combined with hormone therapy for people aged 60 or older with hormone receptor-positive, HER2-negative metastatic breast cancer. The goal is to see how well this treatment works and to gather information that may help improve dosing for older adults.
Englewood, New JerseyAges 60 years+ - NCT06139107RecruitingPhase 1
Radiation and abemaciclib plus letrozole before breast cancer surgery
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Belleville, New JerseyAges 60 years+
Where these studies are running in New Jersey
Institutions with a site for the recruiting her2 + breast cancer studies listed above.
- Rutgers Cancer Institute of New Jersey · 8 studies
- Overlook Medical Center - Atlantic Health System · 4 studies
- Summit Health · 4 studies
- Capital Health Medical Center - Hopewell · 3 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 3 studies
- MD Anderson Cancer Center at Cooper · 3 studies
- Memorial Sloan Kettering Basking Ridge · 3 studies
- Memorial Sloan Kettering Bergen · 3 studies
What taking part in a her2 + breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
HER2 + Breast Cancer trials in other states
Common questions
- Are there her2 + breast cancer clinical trials in New Jersey?
- Yes. We're currently tracking 76 recruiting her2 + breast cancer studies with a site in New Jersey, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a her2 + breast cancer study in New Jersey?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New Jersey to take part?
- Not necessarily. These studies have a site in New Jersey, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a her2 + breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New her2 + breast cancer studies open in New Jersey regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.